Consumers tell CCB to require solvent testing and share complaint outcomes

Several members of the public told the Cannabis Control Board they are concerned about solvent residues in cannabis products and about transparency in the agency's complaint process.

Steve Owens, who identified himself as representing Oracle Corporation, told the board Oracle has entered the cannabis market and offers a regulatory ecosystem that includes licensing, automated licensing, embedded compliance and enforcement, case management and embedded AI. "We have a cannabis regulatory ecosystem which includes licensing, automated licensing, embedded compliance and enforcement, case management, and also embedded AI," Owens said and asked to discuss potential opportunities with the board.

Tom Elgis spoke for himself and said he had filed complaint CMP2600096. He told the board he used a cannabis extract to manage anxiety after a heart-failure diagnosis and said he experienced headaches and other symptoms he attributes to residual solvents. Elgis said testing often does not include solvents and that consumers and complainants should be able to see test results. "In short, ingesting or inhaling butane or propane can be absolutely life threatening and can cause sudden deaths," he said, and asked the board to require solvent testing and to allow complainants to be informed of investigation outcomes.

Board members thanked the speakers; the meeting record shows staff will continue to process complaints under existing procedures. The public commenter requested access to laboratory tests and more transparency about complaint resolutions; the transcript does not record an immediate policy change or staff commitment to alter disclosure practices.

The board closed public comment and proceeded with agenda business.